Ultragenyx Pharmaceutical (RARE) Share-based Compensation (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Share-based Compensation data on file, last reported at $30.0 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 25.0% year-over-year to $30.0 million in Q1 2026; TTM through Mar 2026 was $142.9 million, a 11.27% decrease from a year earlier, with the FY2025 full-year figure at $153.0 million, down 3.16% from the prior year.
• Share-based Compensation for Q1 2026 stood at $30.0 million, down from $37.3 million in the prior quarter.
• Over the last five years, Share-based Compensation for RARE reached as high as $41.6 million in Q3 2024 and fell as low as $1.6 million in Q1 2022.
• Historically, Share-based Compensation has averaged $30.3 million across 5 years, with a median of $35.8 million in 2022.
• Across the five-year window, Share-based Compensation plunged 93.49% in 2022 and surged 1335.75% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $29.4 million in 2022, then gained by 14.23% to $33.5 million in 2023, then climbed by 19.69% to $40.1 million in 2024, then declined by 7.09% to $37.3 million in 2025, then declined by 19.55% to $30.0 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $30.0 million in Q1 2026, $37.3 million in Q4 2025, and $37.0 million in Q3 2025.